Kiora Pharmaceuticals, Inc. (KPRX)
NASDAQ · Manufacturing · Pharmaceutical preparations
KPRX price, last 12 months
Key stats
- Previous close
- $0.8248
- Open
- $0.8300
- Day range
- $0.8050 – $0.8757
- 52-week range
- $0.7202 – $2.91
- Volume
- 27.7K
- Avg volume (20 days)
- 80.1K
- Market cap
- $5.4M
Performance
Technicals and fundamentals
About Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $5.4M